ANI Pharmaceuticals, Inc. (ANIP) Cash Flow Statement

The OCF/NI ratio of 2.29 in 2026Q2, up from 1.98 in the prior quarter, indicates that reported earnings are backed by strong cash generation. This is particularly notable given the $21.6M stock-based compensation, which is a non-cash expense, and the positive working capital contribution of $6.4M. The sustained conversion suggests that the company's accruals are not inflating earnings, and the cash flow is a reliable indicator of underlying profitability.

The FCF trajectory is robust, with 2026Q2 FCF of $68.0M representing a significant jump from $47.1M in 2026Q1 and $6.5M in 2025Q4. This improvement is driven by strong operating cash flow of $56.7M and modest capex of $6.1M. The FCF margin of 25.6% is well above the peer average, indicating that the company is efficiently converting revenue into cash, likely benefiting from the high-margin Rare Disease segment.

CapEx/Revenue has remained in a tight range of 1.3% to 3.8% over the past ten quarters, with 2026Q2 at 2.3%. This indicates that the company is not heavily investing in new capacity, which is consistent with its existing manufacturing infrastructure. The low capex relative to revenue and D&A (which averaged $20M per quarter) suggests that maintenance capex is well below depreciation, potentially allowing for higher distributable cash flow, though investors should monitor whether this underinvestment could impair future growth.

The working capital line has been erratic, with large negative contributions in 2025Q4 and 2025Q3, and a positive contribution in 2025Q2. This volatility likely stems from the timing of receivables and payables, particularly given the rapid revenue growth and the launch of Cortrophin. The positive $6.4M in 2026Q2 suggests improved collections or inventory management, but the inconsistency warrants monitoring for potential channel stuffing or inventory build-up that could distort cash flow.

The company has not paid dividends in the last ten quarters, and buybacks have been negligible, with the largest repurchase being $19.8M in 2026Q1. Instead, cash is being directed toward organic growth, such as the sales force expansion, and potential M&A, as evidenced by the $393.1M acquisition in 2024Q3. This deployment strategy aligns with the company's focus on scaling its Rare Disease franchise, though the lack of shareholder returns may be a consideration for income-focused investors.

The cumulative gap between operating cash flow and net income is substantial, with OCF totaling $364.5M versus net income of $111.2M. This divergence is largely due to non-cash charges like D&A and SBC, as well as working capital swings. The strong cash generation relative to earnings suggests that the company's profitability is understated by accounting rules, and the cash flow is more reflective of the underlying economic performance, which is a positive signal for valuation.